Recurrent spontaneous abortion (RSA) refers to two or more consecutive spontaneous abortions, and is a common complication of pregnancy. 40% to 80% of RSA cannot be found clinically, and is called unexplained recurrent spontaneous abortion (URSA). The majority of the cases of RSA have no clear clinical cause and are called unexplained recurrent spontaneou abortion (URSA). According to the existing level of statistics from different regions, classes and ages, the incidence of spontaneous abortion is 15-40%, and those occurring before 12 weeks of gestation account for 62%, and the actual incidence may be higher because the occurrence of subclinical spontaneous abortion is difficult to estimate, which has become an important cause of harm to women’s reproductive health. Recent studies have confirmed that the success of pregnancy depends on the immune tolerance of the pregnant woman to the embryonic semi-identical antigens, and that the immune tolerance in normal pregnancy involves the interplay of many factors, any of which can lead to the disturbance of maternal-fetal immune regulation, which can lead to the rejection of the embryo with alloantigens, resulting in miscarriage. With the progress of research in reproductive immunology, the causes of RSA are mostly related to immune factors, except for a few chromosomal and genetic abnormalities of both spouses, luteal insufficiency of the female and organic lesions of the uterus. The treatment of URSA is also focused on immunology. In addition to donor and spouse lymphocyte immunization, we can also import concentrated leukocytes of the same blood type, whole blood, single nucleated cells, trophoblast syncytium, and activated autoimmune blood as active immune sources, and we can also import immunoglobulin for passive immunization and immunosuppressive therapy for autoimmune abnormalities. Active immunotherapy is currently recognized as the most effective method, which can increase the level of maternal closed antibodies, change the composition of immune cell subpopulation ratio, improve the patient’s immune response, so that the embryo is protected, and its immune responsiveness is strong. Our hospital is the first one to carry out the application of active immunotherapy in Huzhou region, in order to solve the urgent needs of URSA patients in Huzhou region, using lymphocyte active immunotherapy to increase the level of closed antibodies in the patient’s body, change the composition ratio of immune cell subpopulation, improve the patient’s immune response, and combine with the conventional fetal preservation and antifetus program to increase the success rate of second pregnancy, reduce the incidence of recurrent miscarriage in the region, and Improve the technical level of our city in the field of infertility and eugenics.